In brief
Federal authorities have green-lighted a generic form of the abortion pill mifepristone, prompting criticism from anti-abortion groups. The move follows earlier approvals and underscores ongoing tensions surrounding reproductive healthcare regulations under both Trump and Biden administrations. The FDA has been requested to review the drug's safety amidst calls from abortion opponents.
In a significant development, the U.S. Food and Drug Administration (FDA) has approved a new generic version of mifepristone, a drug used in abortion procedures. This approval has reignited strong reactions from anti-abortion organizations, who view the decision as a troubling endorsement of what they consider an unethical practice.
Evita Solutions, the company behind the generic version, announced on its website that the FDA's endorsement facilitates its low-cost offerings for the medication, which is intended for use up to ten weeks into a pregnancy.
Opposition often comes from groups like Students for Life Action, who labeled the move as detrimental to the legacy of former President Donald Trump, arguing for a reevaluation of the drug's safety record.
Previous health officials under Trump's administration, including Secretary Robert F. Kennedy Jr., have faced increasing demands from abortion opponents to reassess mifepristone, which has been on the market for over two decades with a history of being deemed safe and effective.
In another related action, Kennedy and FDA Commissioner Dr. Marty Makary communicated a commitment to an extensive review of the drug's safety in a letter to Republican attorneys general.
Since its initial approval in the year 2000, mifepristone's access has gradually expanded, including the introduction of an earlier generic version by GenBioPro in 2019.
Notably, in 2021, the FDA expanded access through online prescriptions and mail-order delivery, greatly enhancing availability amid persistent resistance from anti-abortion proponents.
While the approval of generic drugs typically undergoes a standard process, the lengthy timeline for Evita Solutions, which submitted its application four years prior, stands out in this case.
Despite the generics' approval, access to mifepristone faces ongoing restrictions owing to state laws that impose various barriers, often unsupported by mainstream medical organizations such as the American Medical Association.
